BS_MY9D8XZ1
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 29.139290407358736
- age_years
- 17.636
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.495
- PROTEIN_SECRETION+0.459
- INTERFERON_GAMMA_RESPONSE+0.443
- INFLAMMATORY_RESPONSE+0.434
- IL6_JAK_STAT3_SIGNALING+0.419
- TNFA_SIGNALING_VIA_NFKB+0.402
- ALLOGRAFT_REJECTION+0.397
- TGF_BETA_SIGNALING+0.360
- COMPLEMENT+0.358
- BILE_ACID_METABOLISM+0.357
Top 10 suppressed
- MYC_TARGETS_V2-0.539
- E2F_TARGETS-0.534
- G2M_CHECKPOINT-0.460
- MYC_TARGETS_V1-0.391
- DNA_REPAIR-0.271
- SPERMATOGENESIS-0.253
- WNT_BETA_CATENIN_SIGNALING-0.134
- UNFOLDED_PROTEIN_RESPONSE-0.094
- PANCREAS_BETA_CELLS-0.084
- MITOTIC_SPINDLE-0.066
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Q79NP5YY | pilocytic astrocytoma | — | 0.951 |
| 2 | BS_NRPG5K4K | low-grade glioma | — | 0.950 |
| 3 | BS_V89HGTET | pilocytic astrocytoma | — | 0.948 |
| 4 | BS_X16PENSA | pilocytic astrocytoma | — | 0.945 |
| 5 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.940 |
| 6 | BS_014EVM2D | low-grade glioma | — | 0.939 |
| 7 | BS_4HQ3T2NC | pilocytic astrocytoma | — | 0.937 |
| 8 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.937 |
| 9 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.937 |
| 10 | BS_VW85Q4XJ | low-grade glioma | — | 0.935 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.495 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.459 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.443 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.434 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.419 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.402 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.397 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.358 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.357 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.354 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.344 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.324 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.323 | Inavolisib | — uncovered |
| HYPOXIA | 0.315 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.303 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.273 | Remibrutinib | — uncovered |
| COAGULATION | 0.271 | Binimetinib | — uncovered |
| MYOGENESIS | 0.263 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.258 | Inavolisib | — uncovered |